Renascience

Renascience FCF Growth

The Year-over-Year Free Cash Flow Growth of Renascience (4889.T) as of Nov 19, 2026 is -64.45 %. In the previous year, Year-over-Year Free Cash Flow Growth was 23.68 % — a change of -372.19% (lower).

FCF Growth

-64.45 %

YoY

-372.19%

Last updated:

Year-over-Year Free Cash Flow Growth of Renascience is 2026 -64.45 % . Year-over-Year Free Cash Flow Growth of Renascience was 2025 23.68 % . It decreases by -372.19% lower compared to the previous year.

The Renascience FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2021
49.38 JPY
Jan 1, 2022
-156.64 JPY
Jan 1, 2023
-23.83 JPY
Jan 1, 2024
19.09 JPY
Jan 1, 2025
23.68 JPY
Jan 1, 2026
-64.45 JPY
The Renascience FCF Growth history
YEARFCF GrowthYoY
-64.45 %-372.19%
23.68 %+24.02%
19.09 %-180.11%
-23.83 %-84.79%
-156.64 %-417.22%
49.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Year-over-Year Free Cash Flow Growth of Renascience is -64.45 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Renascience since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Renascience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Renascience

All Key Metrics — Renascience